Value & Innovation Forum

The Value & Innovation Forum is a collaboration of the National Forum for Heart Disease & Stroke Prevention and Patient Advocate Foundation, both 501(c)(3) nonprofit organizations. Briefing topics are selected by the Value & Innovation Forum Steering Committee which includes representatives of the Alliance of Community Health Plans and Association of Black Cardiologists, in addition to the National Forum and Patient Advocate Foundation. Briefings are made possible by funding from Amgen in accordance with the National Forum’s Policy on Corporate and Foundation Support and Relationships. This policy ensures transparency and integrity in the National Forum’s dealings with sponsors.


Value & Innovation Forum Briefings

Watch Recording

Resources

Briefings Archive

Navigating the Complexities of Medicaid Redeterminations - May 19, 2023

MODERATOR
  •  Julie Rovner
    • Chief Washington Correspondent, KFF Health News
PANELISTS
RESOURCES
Medicaid Redeterminations - April 14, 2023

WATCH RECORDING

  •  MODERATOR
    • Nissa Shaffi, Associate Director of Public Policy, Alliance of Community Health Plans
  • PANELISTS
    • William Schpero, PhD, Assistant Professor of Population Health Sciences at Weill Cornell Medical College
    • Matt Powers, Managing Director at Health Management Associates
    • Sally Mabon, Senior Program Director at the Center for Health and Wellbeing at Princeton University

RESOURCES:

Current State Of Transparency in Health Care Pricing - March 1, 2023

Watch Recording

RESOURCES:

 

Increasing Minority Patient Involvement in Research - February 1, 2022

Webinar Recording

SPEAKERS:

Moderator: Edward Ivy, MD, Director, Community Programs Committee,​ 
@Association of Black Cardiologists

Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA, Gerald S. Berenson Endowed Chair in Preventive Cardiology, Professor of Medicine @Tulane University School of Medicine

Richard Towne, PharmD, Clinical Informatics Manager @Antidote

Fortunato Fred Senatore, MD, PhD, FACC
Lead Physician, Division of Cardiology & Nephrology​ @U.S. Food & Drug Administration
Lakshmanan Krishnamurti, MD
Pediatric Hematologist Oncologist @Yale Department of Pediatrics and Yale New Haven Children’s Hospital

 

RESOURCES:

Improving the enrollment of women and racially/ethnically diverse populations in cardiovascular clinical trials: An ASPC practice statement – December 2021

Increasing Diversity in Clinical Trials: Overcoming Critical Barriers – November 2021

Drug Trials Snapshots

Slides from Webinar

 

 

Edward Ivy, MD Excerpt

Keith C. Ferdinand, MD Excerpt

Fred Senatore, MD Excerpt

Lakshmanan Krishnamurti, MD Excerpt

Richard Towne, PharmD Excerpt

Biosimilars: Incentives, Competition, Patient Access & Health Equity - December 13, 2021

Webinar Recording / Webinar Summary (To Be Added Soon!)

SPEAKERS:

Moderator: John Clymer, Executive Director, National Forum

Juliana Reed, President of Biosimilars Forum

Zeid El-Kilani, Economist, US Department of Health and Human Services

Chad Pettit, Executive Director Marketing, Global Biosimilars Commercial Lead, Amgen

Robert Lash, Chief Medical Officer, Endocrine Society

RESOURCES:

Biosimilars Forum report October 2021

Health Affairs Article June 2021

Endocrine Society Statement

Amgen 2021 Biosimilars Report

What Are Z Codes and How Do They Impact Health Equity? - September 21, 2021

 

Webinar Recording | Webinar Summary


Speaker Bios

Alan Balch, PhD, Chief Executive Officer, Patient Advocate Foundation & National Patient Advocate Foundation

Julia Resnick, Senior Program Manager for Strategic Initiatives, American Hospital Association

Katlyn Sollenberger, Site Specialist, The Rinehart Clinic, Wheeler, OR


Resources

Proposed New Codes for SDOH Z Codes

2021 ICD-10-CM from CMS

Z Codes Infographic from CMS

Kaiser Permanente Infographic on Z Codes

American Hospital Association ICD-10-CM Coding for Social Determinants of Health

Telehealth: Patient Access & Equity - June 2, 2021

Webinar Recording | Webinar Summary


Speaker Bios

Shonta Chambers, MSW
Executive Vice President, Health Equity & Community Engagement
Principal Investigator, SelfMade Health Network
Patient Advocate Foundation

Barbara Hutchinson, MD PhD, FACC
President, Chesapeake Cardiac Care
Past President, Association of Black Cardiologists

Connie Hwang, MD, MPH
Chief Medical Officer, Director of Clinical Innovation
Alliance of Community Health Plans


Resources

Patient Advocate Foundation Telehealth Tip Sheet

ACHP Fact Sheet – The Promise of Telehealth (April 2021)

Regional Payers Outline Challenges, Successes of Telehealth Implementation (AJMC Feb 2021)

Nonprofit Health Plans Launch Telehealth-First Options to Increase Access and Affordability (NEJM Catalyst April 2021)

Innovations and Alternatives to Traditional Utilization Management - December 14, 2020

Webinar Recording | Webinar Summary


Traditional utilization management has become burdensome for physicians and patients.  This 1-hour briefing brings forward innovative real-world examples to navigate utilization management.

Speakers

Kate Berry, Senior Vice President of Clinical Innovation, America’s Health Plans
Jay Scott, Director, Managed Care, Minnesota Oncology
Robin T. Zon, MD, FACP, FASCO Chair, ASCO Pathways Task Force
President, Finance & Quality Chair, Michiana Hematology-Oncology, PC


Moderator

Alan Balch, PhD, CEO, Patient Advocate Foundation, National Patient Advocate Foundation


Resources

American Society of Clinical Oncology (ASCO) Policy Statement On the Impact of Utilization Management Policies for Cancer Drug Therapies

America’s Health Insurance Plans (AHIP) Fast Prior Authorization Technology Highway (Fast PATH)

Journal Article: Streamlining and Reimagining Prior Authorization Under Value-Based Contracts: A Call to Action From the Value in Healthcare Initiative’s Prior Authorization Learning Collaborative

Navigating Cancer

Uptake and Pricing of Biosimilars & the "Rebate Wall": A Value & Innovation Forum Multi-Perspective Briefing - June 2, 2020

Webinar Recording | Webinar Summary | Slides


Biosimilars continue to be a controversial subject long after Congress created a pathway for their approval. The Value & Innovation Forum prides itself on creating forums that present all sides of an issue as well as new and interesting angles beyond the hotly debated. This session provides an interesting discussion about the “rebate wall” controversy in biosimilars, a patient perspective, and where the FDA is headed next.

Speakers

John M. Clymer, Executive Director, National Forum for Heart Disease & Stroke Prevention

Nicole Braccio, PharmD, Policy Director, National Patient Advocate Foundation

Christine Simmon, JD, Senior Vice President, Policy & Strategic Alliances, Executive Director, Biosimilars Council, Association for Accessible Medicines

Sarah Yim, MD, Director, Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation & Research, U.S. Food and Drug Administration

Chad Pettit, Executive Director, Global Value Access and Policy, Amgen

Madelaine Feldman, MD, Practicing Rheumatologist, Founding Member & Past President, Rheumatology Alliance of Louisiana

Agenda


WELCOME

John M. ClymerJohn M. Clymer, Executive Director, National Forum for Heart Disease & Stroke Prevention
Bio


MODERATOR

Nicole Braccio, PharmD, Policy Director, National Patient Advocate Foundation
Bio


Panelists

Christine Simmon, Senior Vice President, Policy & Strategic Alliances, Executive Director, Biosimilars Council, Association for Accessible Medicines
Bio


Sarah Yim, MD, Director, Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation & Research, U.S. Food and Drug Administration
Bio


Chad Pettit, Executive Director, Global Value Access and Policy, Amgen
Bio


Madelaine Feldman, MD, Practicing Rheumatologist, President, Coalition of State Rheumatology Organizations
Bio


Articles

Formulary Construction in America: ‘Perfectly Legal’ and ‘Perfectly Wrong

Op-Ed: Debate Over Pharmacy Benefit Managers a Matter of Price vs. Cost

Washington Must Change the System That Encourages High Drug Prices


White Paper

Lessons for the United States on Europe’s Biosimilar Experience


Websites

FDA Biosimilars for access to educational materials and information about biosimilar and interchangeable products.

Drugs@FDA for information on all FDA approved drug products, including labeling and review information.

FDA Advisory Committees for drug advisory committee meetings and materials related to biosimilars

FDA Purple Book a database of Licensed Biological Products for information on biological products, including if products are biosimilar to a reference product.

Amgen Biosimilars